FDA deputy commissioner Namandjé Bumpus to leave agency

Namandjé Bumpus, principal deputy commissioner of the Food and Drug Administration, is leaving the agency. Commissioner Robert Califf shared the news with staff Tuesday morning, according to an email reviewed by STAT.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Muscle fat infiltration predicts heart disease risk better than BMI, study finds

Skeletal muscle fat infiltration (IMAT) is linked to coronary microvascular dysfunction and increased cardiovascular risk, independent of BMI and traditional risk factors.

January 22, 2025

Merck to acquire Harpoon Therapeutics for $680 million

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just

January 8, 2024

FDA OKs Another Injectable for Rare Kidney Disorder

Nedosiran (Rivfloza), a once-monthly RNA interference (RNAi) injection, gained FDA approval for certain patients with primary hyperoxaluria type 1 (PH1), drugmaker Novo Nordisk announced Monday.

October 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.